i-Lumen Scientific — Novel Retinal Therapy for Age-Related Macular Degeneration
i-Lumen Scientific developed an innovative therapeutic approach for age-related macular degeneration (AMD), the leading cause of vision loss in adults over 50. bioaccess® managed clinical studies in Latin America to generate early human evidence.
Study facts
- Sponsor / company: i-Lumen Scientific
- Indication / area: Ophthalmology
- Country: Colombia
- Study type: Early Feasibility Study (EFS)
Key metrics
- Trial Type: EFS
- Indication: AMD
- Patients Affected: 200M+
- Approval Time: 6 weeks
The challenge
AMD affects over 200 million people globally with limited treatment options for dry AMD. i-Lumen needed early human feasibility data to validate their novel approach and attract ophthalmology-focused strategic partners and investors.
bioaccess® solution
bioaccess® identified retinal surgery centers in Colombia with AMD patient populations, managed regulatory submissions, coordinated treatment delivery, and oversaw optical coherence tomography (OCT) and visual acuity follow-up assessments aligned with FDA standards.
Results
- Early feasibility study completed with encouraging visual outcomes
- Safety profile validated in AMD patients
- OCT imaging confirmed treatment mechanism of action in humans
- Data supported investor presentations and partnership discussions
- Regulatory and ethics approval obtained in under 6 weeks
Frequently asked
- What did bioaccess® do for i-Lumen Scientific?
- bioaccess® identified retinal surgery centers in Colombia with AMD patient populations, managed regulatory submissions, coordinated treatment delivery, and oversaw optical coherence tomography (OCT) and visual acuity follow-up assessments aligned with FDA standards.
- Where was the i-Lumen Scientific Early Feasibility Study (EFS) study run?
- The i-Lumen Scientific Early Feasibility Study (EFS) study was executed in Colombia by bioaccess® in the ophthalmology area.
- What was the outcome of the i-Lumen Scientific study?
- Reported outcomes for i-Lumen Scientific's device: Early feasibility study completed with encouraging visual outcomes; Safety profile validated in AMD patients; OCT imaging confirmed treatment mechanism of action in humans.
Run a similar trial: Clinical trials in Colombia
First-in-Human Clinical Trials pillar · LATAM FIH Benchmarks 2026 · ← All case studies · Contact bioaccess®